Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8

Annals of the New York Academy of Sciences

Volumn 1237, Issue 1, 2011, Pages 88-94

  Ivashkiv, Lionel B ^a,b   Zhao, Baohong ^a   Park Min, Kyung Hyun ^a   Takami, Masamichi ^c  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Weill Cornell Graduate School of Biomedical Sciences   (United States)

^c SHOWA UNIVERSITY   (Japan)

Author keywords

C Fms; Inflammation; IRF8; M CSF; Osteoclasts; Toll like receptors

Indexed keywords

COLONY STIMULATING FACTOR RECEPTOR; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERLEUKIN 10; MEMBRANE RECEPTOR; PROTEIN TREM 2; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; DOWN REGULATION; GENETIC TRANSCRIPTION; HUMAN; INFLAMMATION; NEGATIVE FEEDBACK; NONHUMAN; OSTEOCLASTOGENESIS; PROTEIN EXPRESSION; PROTEIN INDUCTION;

EID: 81255197363     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06217.x     Document Type: Article

References (45)

1. Herman, S., G. Kronke & G. Schett 2008. Molecular mechanisms of inflammatory bone damage: emerging targets for therapy. Trends Mol. Med. 14: 245-253.
2. Hardy, R. & M.S. Cooper 2009. Bone loss in inflammatory disorders. J. Endocrinol. 201: 309-320.
3. Lerner, U.H. 2006. Inflammation-induced bone remodeling in periodontal disease and the influence of post-menopausal osteoporosis. J. Dent. Res. 85: 596-607.
4. Diarra, D. et al 2007. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13: 156-163.
5. Takayanagi, H. 2009. Osteoimmunology and the effects of the immune system on bone. Nat. Rev. Rheumatol. 5: 667-676.
6. Tanaka, S. et al 2005. Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol. Rev. 208: 30-49.
7. Boyce, B.F. & L. Xing 2008. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch. Biochem. Biophys. 473: 139-146.
8. Teitelbaum, S.L. 2006. Osteoclasts; culprits in inflammatory osteolysis. Arthritis Res. Ther. 8: 201.
9. Lorenzo, J., M. Horowitz & Y. Choi 2008. Osteoimmunology: interactions of the bone and immune system. Endocr. Rev. 29: 403-440.
10. Wei, S. et al 2005. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115: 282-290.
11. Kim, J.H. et al 2009. The mechanism of osteoclast differentiation induced by IL-1. J. Immunol. 183: 1862-1870.
12. Danks, L. et al 2011. Elevated cytokine production restores bone resorption by human Btk-deficient osteoclasts. J. Bone Miner. Res. 26: 182-192.
13. Yarilina, A. et al 2011. TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages. Proc. Natl. Acad. Sci. USA 108: 1573-1578.
14. Ochi, S. et al 2007. Pathological role of osteoclast costimulation in arthritis-induced bone loss. Proc. Natl. Acad. Sci. USA 104: 11394-11399.
15. Ivashkiv, L.B. 2011. Inflammatory signaling in macrophages: transitions from acute to tolerant and alternative activation tates. Eur. J. Immunol. 41: 2477-2481.
16. Liew, F.Y. et al 2005. Negative regulation of toll-like receptor-mediated immune responses. Nat. Rev. Immunol. 5: 446-458.
17. Park-Min, K.H. et al 2009. IL-10 suppresses calcium-mediated costimulation of receptor activator NF-kappa B signaling during human osteoclast differentiation by inhibiting TREM-2 expression. J. Immunol. 183: 2444-2455.
18. Koga, T. et al 2004. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428: 758-763.
19. Mocsai, A. et al 2004. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl. Acad. Sci. USA 101: 6158-6163.
20. Paloneva, J. et al 2003. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J. Exp. Med. 198: 669-675.
21. Cella, M. et al 2003. Impaired differentiation of osteoclasts in TREM-2-deficient individuals. J. Exp. Med. 198: 645-651.
22. Kalliolias, G.D. et al 2010. Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum. 62: 402-413.
23. Zou, W. & Z. Bar-Shavit 2002. Dual modulation of osteoclast differentiation by lipopolysaccharide. J. Bone Miner. Res. 17: 1211-1218.
24. Zou, W. et al 2002. CpG oligonucleotides: novel regulators of osteoclast differentiation. FASEB J. 16: 274-282.
25. Takami, M. et al 2002. Stimulation by toll-like receptors inhibits osteoclast differentiation. J. Immunol. 169: 1516-1523.
26. Liu, J. et al 2009. Molecular mechanism of the bifunctional role of lipopolysaccharide in osteoclastogenesis. J. Biol. Chem. 284: 12512-12523.
27. Ji, J.D. et al 2009. Inhibition of RANK expression and osteoclastogenesis by TLRs and IFN-gamma in human osteoclast precursors. J. Immunol. 183: 7223-7233.
28. James, D.E. et al 2010. The relative timing of exposure to phagocytosable particulates and to osteoclastogenic cytokines is critically important in the determination of myeloid cell fate. J. Immunol. 185: 1265-1273.
29. Lee, B. et al 2010. Direct inhibition of human RANK+ osteoclast precursors identifies a homeostatic function of IL-1beta. J. Immunol. 185: 5926-5934.
30. Tamura, T. & K. Ozato 2002. ICSBP/IRF-8: its regulatory roles in the development of myeloid cells. J. Interferon Cytokine Res. 22: 145-152.
31. Zhao, B. et al 2009. Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nat. Med. 15: 1066-1071.
32. Kantakamalakul, W. et al 1999. Regulation of IFN consensus sequence binding protein expression in murine macrophages. J. Immunol. 162: 7417-7425.
33. Zhao, J. et al 2006. IRF-8/interferon (IFN) consensus sequence-binding protein is involved in Toll-like receptor (TLR) signaling and contributes to the cross-talk between TLR and IFN-gamma signaling pathways. J. Biol. Chem. 281: 10073-10080.
34. Taylor, P.C. & M. Feldmann 2009. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat. Rev. Rheumatol. 5: 578-582.
35. Locksley, R.M., N. Killeen & M.J. Lenardo 2001. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104: 487-501.
36. Schett, G. & S.L. Teitelbaum 2009. Osteoclasts and arthritis. J. Bone Miner. Res. 24: 1142-1146.
37. Yao, Z. et al 2006. Tumor necrosis factor-alpha increases circulating osteoclast precursor numbers by promoting their proliferation and differentiation in the bone marrow through up-regulation of c-Fms expression. J. Biol. Chem. 281: 11846-11855.
38. Boyce, B.F., E.M. Schwarz & L. Xing 2006. Osteoclast precursors: cytokine-stimulated immunomodulators of inflammatory bone disease. Curr. Opin. Rheumatol. 18: 427-432.
39. Kobayashi, K. et al 2000. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191: 275-286.
40. Li, J. et al 2000. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97: 1566-1571.
41. Li, P. et al 2004. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J. Bone Miner. Res. 19: 207-213.
42. Kim, N. et al 2005. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J. Exp. Med. 202: 589-595.
43. Zhao, B. & L.B. Ivashkiv 2011. Negative regulation of osteoclastogenesis and bone resorption by cytokines and transcriptional repressors. Arthritis Res. Ther. 13: 234-244.
44. Soysa, N.S. et al 2010. The pivotal role of the alternative NF-kappaB pathway in maintenance of basal bone homeostasis and osteoclastogenesis. J. Bone Miner. Res. 25: 809-818.
45. Yao, Z., L. Xing & B.F. Boyce 2009. NF-kappaB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J. Clin. Invest. 119: 3024-3034.